FDA Inspection 1324204 — Direct Rx
The FDA completed an inspection of Direct Rx on June 4, 2026 in Dawsonville, GA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- June 4, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Dawsonville, GA (United States)